Wang Y, Li M, Wang Y
Southwest Hospital, Third Military Medical College, Chongqing.
Zhonghua Gan Zang Bing Za Zhi. 1999 Mar;7(1):31-3.
To establish an extracorporeal bioartificial liver support system (EBLSS) and study its support effect for fulminant hepatic failure (FHF).
The EBLSS consists of three parts: human liver cells (hepatocytes, nonparenchymal hepatocytes) isolated and cultured by extracorporeal two-stage perfusion and spheroidal aggregates methods respectively, hollow fiber bioreactor, and supplementary circulation unit, which was employed to support the FHF model dogs.
Compared with the control dogs treated with EBLSS but without liver cells, the survival time of artificial liver support dogs was significantly prolonged, the changes of blood pressure, heart rate and ECG were slower, and the serum ammonia and lactate levels were significantly lower at the 3 and 5 hr. In addition, a good viability of human liver cells was noted after 5 hr experiment.
This EBLSS has played the metabolic role of cultured heman hepatocytes, is capable of compensating the function of the liver, and might provide effective artificial liver support and therapy for patients with FHF or severe hepatitis.
建立一种体外生物人工肝支持系统（EBLSS），并研究其对暴发性肝衰竭（FHF）的支持效果。
EBLSS由三部分组成：分别采用体外两步灌注法和球状体聚集法分离培养的人肝细胞（肝细胞、非实质肝细胞）、中空纤维生物反应器和辅助循环单元，用于支持FHF模型犬。
与接受EBLSS但无肝细胞治疗的对照犬相比，人工肝支持犬的生存时间显著延长，血压、心率和心电图的变化较慢，在3小时和5小时时血清氨和乳酸水平显著降低。此外，实验5小时后观察到人类肝细胞具有良好的活力。
该EBLSS发挥了培养的人肝细胞的代谢作用，能够代偿肝脏功能，可能为FHF或重型肝炎患者提供有效的人工肝支持和治疗。
